KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition. Br J Cancer. 2014;111:1788-801.Hamidi H, Lu M, Chau K, Anderson L, Fejzo M, Ginther C, et al. KRAS mutational subtype and copy number predict in vitro response ...
Melanophilin-induced primary cilia promote pancreatic cancer metastasis Yu-Ying Chao Ruei-Ci Lin Chia-Yih Wang ResearchOpen Access16 Jan 2025 Cell Death & Disease Volume: 16, P: 22 Anti-proteolytic regulation of KRAS by USP9X/NDRG3 in KRAS-driven cancer development The regulation of KRA...
Pancreatic cancer has the highest frequency of KRAS mutations but the prevailing KRAS G12D mutation is difficult to target. Inhibition of the GTP exchange factor (GEF) SOS1—KRAS interaction impairs oncogenic signaling independently of the specific KRAS mutations. In general, cell lines exhibiting ...
Mark Erlander, PhD, Chief Scientific Officer, Trovagene, discusses a study looking at the association between ctDNA KRAS mutation levels and outcomes in patients with non-resectable pancreatic cancer. Mark Erlander, PhD, Chief Scientific Officer, Trovagene, discusses a study looking at the ...
Common mutation targets in PDAC include KRAS, TP53, SMAD4 and CDKN2A, with KRAS mutations occurring in over 90% of PDAC patients, thereby constituting an attractive target for neoantigen-based vaccines [115]. Targeting KRAS mutant protein with a single- or poly-peptide vaccine in combination ...
Pancreatic cancer is a highly lethal disease with a poor prognosis, and existing therapies offer only limited effectiveness. Mutation gene sequencing has shown several gene associations that may account for its carcinogenesis, revealing a promising resea
Bekaii-Saab, T. S. et al. KRYSTAL-1: updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12Cmutation [abstract].J. Clin. Oncol.40(Suppl. 4), 519 (2022)...
PDAC onset and progression were investigated in wild type syngeneic mice receiving into pancreata pre-neoplastic lesion-derived organoids from PanIN-bearing Pdx1-Cre; Kras+/LSL−G12D; Trp53+/LSL−R172H (KPC) mice, which well recapitulate human PDAC pathogenesis [56] and the stepwise progres...
The results of PNA-directed PCR clamping applied to cancer cell lines and sera of cancer-free donors indicated that a sample could be considered positive for KRAS mutations if the Ct number was o35 when 2 ng cfDNA was used. Patient characteristics and KRAS mutation status. In total, 84 ...
Increased SRC expression positively correlates with chemoresistance in human pancreatic cancer cell lines [126], while oncogenic KRAS mutations induce a SRC-dependent amplification loop that promotes metastasis and therapy resistance in human PDAC tumors [127]. Conversely, therapeutic or siRNA-mediated SRC...